Bioxcel therapeutics receives fda fast track designation for bxcl701 for treatment of small cell neuroendocrine prostate cancer (scnc)

Designation for bxcl701 in combination with a checkpoint inhibitor (cpi) for treatment of patients with metastatic scnc with progression on chemotherapy and no evidence of microsatellite instability

BTAI Ratings Summary

BTAI Quant Ranking